*Once completed please combine this form, along with optional max 1xA4 page of figures/data tables and proof of lead organisation support, into a single pdf for submission.*

Section 1: Proposal Summary

|  |
| --- |
| 1.1 Title (max. 150 characters) |
|  |

|  |
| --- |
| 1.2 Scientific/technical summary (max. 250 words) |
|  |

|  |
| --- |
| 1.3 List which country/countries on the OECD DAC list of ODA recipients (DAC list) will directly benefit from this proposal. (Please tick the ‘global benefit’ box if also applicable) |
|  |
| Global benefit |

|  |  |  |
| --- | --- | --- |
| 1.4 Which of the UKRI GCRF/Newton Fund portfolio areas is your proposal most aligned to? | | |
|  | Primary | Secondary |
| Resilience |  |  |
| Security Protracted Conflict, Refugee Crises and Forced Displacement |  |  |
| Cities and Sustainable Infrastructure |  |  |
| Food Systems |  |  |
| Education |  |  |
| Global Health |  |  |
| Cross portfolio (If you can, please specify) |  | |

|  |  |
| --- | --- |
| 1.5 Project duration\* | |
| Proposed start date (dd/mm/yy) |  |
| Proposed duration of award (months) |  |
| Proposed end date (dd/mm/yy) |  |

\* note max. 18 months

|  |  |  |  |
| --- | --- | --- | --- |
| 1.6 Project cost (£) | FY 20/21 | FY 21/22 | TOTAL |
| **Indicative costs** |  |  |  |

|  |  |  |
| --- | --- | --- |
| 1.7 Which councils’ remits is your proposal most aligned to? | | |
|  | Primary | Secondary |
| AHRC |  |  |
| BBSRC |  |  |
| EPSRC |  |  |
| ESRC |  |  |
| MRC |  |  |
| NERC |  |  |
| STFC |  |  |
| Don’t know |  |  |

Section 2: Investigator Details

|  |  |
| --- | --- |
| 2.1 Principal Investigator | |
| Name |  |
| PI Organisation |  |
| PI Department |  |
| Country |  |
| Email address |  |
| ORCID (if applicable) |  |
| Administrative authority contact name (email) |  |

|  |  |  |  |
| --- | --- | --- | --- |
| 2.2. Co-Investigators | | | |
| Name | Organisation | Country | Email Address |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |
|  |  |  |  |

|  |  |  |
| --- | --- | --- |
| 2.3 Project Partners (unfunded by proposal, if applicable) | | |
| Project partner organisation | Project Partner Contact | Contribution Type (e.g. access to equipment, samples) |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |
|  |  |  |

\*Please estimate approximate value of partner contribution

|  |
| --- |
| 2.4 Non-UK Principal Investigators: Grant reference number of UKRI grants held by organisation (only include current UKRI grants or previous UKRI grants held up to a maximum of 3 years ago) |
|  |
| **Please note this is a mandatory requirement: If your organisation does not lead and hold/ has not previously led and held a UKRI grant you will not be eligible to apply for this call.** |

Section 3: Importance, Deliverables, Expertise, Resources and ODA Compliance

|  |
| --- |
| 3.1 In the context of the DAC list beneficiary country/countries you have identified, please describe and justify the importance of the COVID-19 related knowledge gap and/or development need that you are targeting (max. 250 words) |
|  |

|  |
| --- |
| 3.2 Please describe how the research impact(s) can be scaled to be useful to your DAC list beneficiary country/countries (with attention to economic development and welfare). Please reference how any impacts will contribute to progress with the United Nations sustainable development goals (SDGs).  (max. 250 words) |
|  |

Section 4: Gender Equality

|  |
| --- |
| 4.1 Gender equality: Outline how you have taken meaningful yet proportionate consideration as to how your proposed activities will contribute to reducing gender inequalities.  (max. 250 words) |
|  |

Section 5 Plan of Research including Importance, Deliverables, and Resources

|  |
| --- |
| 5.1 In this section you should provide an overview of the nature of the proposed research or project in the context of the DAC list beneficiary country/countries you have identified (study design, approach and deliverables) (max. 1500 words).  To include:   * How deliverables will provide/lead to benefit(s) relating to the health, social, economic, cultural and/or environmental impacts of the COVID-19 outbreak within 18 months. * How these are unique and value-adding compared to existing COVID-19 related activities targeting the same or similar knowledge gap(s) and/or need(s) |
|  |

|  |
| --- |
| 5.2 Principal investigator: Please provide a brief description of the resources required in the different contributing environments (staff, materials, data, facilities etc.), including whether these are in hand, or if not, what gives you confidence that they will be accessible when required? (max. 250 words). |
|  |

|  |
| --- |
| 5.3 Partner country: Please provide a brief description of the resources required in the different contributing environments (staff, materials, data, facilities etc.), including whether these are in hand, or if not, what gives you confidence that they will be accessible when required? (please sate N/A if not applicable) (max. 250 words). |
|  |

Section 6: Investigators

|  |
| --- |
| 6.1 Please provide evidence that the team has the necessary expertise, track record and contacts to undertake the proposed work and ensure its impact (max. 250 words). |
|  |

The following should also be provided. **These should be combined with this form into a single pdf for submission** to [GCRFCV19@ukri.org](mailto:GCRFCV19@ukri.org)

**Institutional approvals** Include evidence of approval from the host institution/company/organisation which confirms you are able to carry out the proposed work under any institutional restrictions currently in place.

Annex 1: Regulatory requirements: Please complete as applicable

A. Legislative/Ethical requirements

**Note:** Data produced as a result of this funding must be shared in line with the [Joint statement on sharing research data and findings relevant to the novel coronavirus (nCoV) outbreak](https://wellcome.ac.uk/press-release/sharing-research-data-and-findings-relevant-novel-coronavirus-ncov-outbreak).

|  |  |
| --- | --- |
| Does this programme involve: | |
| **1. Animals?**  The use of vertebrate animals or other organisms covered by the Animals (Scientific Procedures) Act 1986[[1]](#footnote-2), whether or not it requires licensed procedures. | Yes/No |
| **1a. Animal Species?**  If animals are being used please provide the basic species information e.g. Mouse. |  |
| **2. Human Tissue?**  The use of human tissue as defined in the Human Tissue Act 2004[[2]](#footnote-3)? | Yes/No |
| **3. Stem Cells?**  Does the research involve the use of Stem Cells or regenerative medicine? | Yes-both/Yes-embryonic/Yes-adult/No |

Note: The MRC will make public information about animal experiments when needed (e.g. as anonymous examples, or in response to direct queries) but will resist all requests for information that might lead to the identification of places or individuals, except with the express permission of the individuals concerned.

B. Additional information for clinical research

|  |  |
| --- | --- |
| Does this programme involve: | |
| **1. Human participation?**  Research which requires *face-to-face* contact with *patients*, or with *healthy human participants* (by holders of a clinical contract) and may involve use of patient records as a concomitant, e.g. a clinical trial. | Yes/No |
| **2. Records based studies?**  Research which requires *access to personal data* on health or lifestyle *without* involving face-to-face contact with any people, e.g. public health interventions, health economic studies, epidemiological studies, health services research and meta-analyses - information may be obtained by telephone, postal questionnaires/surveys or electronic/manual data retrieval. | Yes/No |
| **3. Clinical samples?**  Research which involves *laboratory studies* on *human material* which are specifically designed to understand or treat a disease/disorder. N.B. Basic biomedical research remote from application to a disease/disorder, such as the use of immortalised human cell lines in model biological systems, is excluded. | Yes/No |
| **4. Technology development for clinical use?**  Development or adaptation of technologies for diagnosis or therapy, e.g. instrument development for diagnostic or surgical use; development of new techniques, such as photodynamic therapy, for clinical use. | Yes/No |

Note: This information will not be made publicly available in an identifiable format.

C. Additional Analysis Data

|  |  |
| --- | --- |
| The following data will assist us in scientific and strategic reporting and may be published. | |
| **Research Setting**  Based on direct patient contact, indicate whether the research involves a particular medical setting such as primary care or secondary care. | None/Other/Emergency/Primary & Secondary/Secondary/Primary |

D. Other ethical considerations

|  |  |  |
| --- | --- | --- |
| Other Ethical Considerations | | |
| Are there other ethical and/or health and safety issues that have been considered | Yes/No |
| **If Yes, please outline (max 100 words)** | |
|  | |
| Is the ethical approval already in place? | Yes/No |
| Will ethics approval be sought and if so when? | Yes/No |

1. <http://www.homeoffice.gov.uk/science-research/animal-research/> [↑](#footnote-ref-2)
2. <https://mrc.ukri.org/research/facilities-and-resources-for-researchers/regulatory-support-centre/human-tissue/> [↑](#footnote-ref-3)